Key Highlights

  • Second-quarter net sales were about $1,023 million, down 3.2% year over year, with Organic Sales also declining.
  • Adjusted Earnings came in below the prior year but ahead of analyst expectations.
  • The Self Care and Specialty Care segments declined, while Infant Formula grew 23.1%, a notable bright spot.
  • Perrigo reaffirmed its full-year 2026 outlook, pointing to a sequentially stronger second half driven by moderating Manufacturing under-absorption.

Perrigo Company (NYSE:PRGO), a leading provider of consumer self-care and over-the-counter health products, reported a quarter that, while showing lower sales, beat estimates and reaffirmed guidance for a stronger second half. For investors, the question is whether this value-oriented self-care company can deliver the recovery it has guided to.

Perrigo develops and manufactures over-the-counter and store-brand self-care products, spanning categories such as cough and cold, pain relief, digestive health and infant nutrition, emphasizing value and affordability. Its store-brand focus positions it to benefit when consumers seek lower-cost alternatives, and it operates across consumer self-care, specialty care and infant-formula segments in the Americas and internationally.

Latest Developments

In its second-quarter 2026 results, Perrigo reported net sales of about $1,023 million, down 3.2% year over year, with organic sales also declining, and adjusted earnings that came in below the prior year but ahead of analyst expectations. By segment, its Self Care and Specialty Care businesses declined, while its Infant Formula segment grew 23.1%, a notable bright spot. The company reaffirmed its full-year 2026 outlook, pointing to a sequentially stronger second half driven by moderating manufacturing under-absorption and more favorable category comparisons.

Financial and Business Position

Perrigo's results reflect a company still working through a period of softer sales, with declines in its core self-care and specialty segments partly offset by strong growth in infant formula. The reaffirmed guidance and the expectation of a stronger second half suggest management sees improving trends ahead, aided by operational factors like reduced manufacturing under-absorption. Perrigo's value-oriented, store-brand positioning gives it a defensible niche in consumer health.

Stock-Market Context

The company carries a favorable analyst rating, reflecting the earnings beat and reaffirmed guidance. The case for a fresh look rests on Perrigo delivering the expected sequentially stronger second half, a recovery in its self-care and specialty segments, continued infant-formula growth, and Margin improvement; the cautionary case is that sales are still declining, and the company must demonstrate a genuine return to organic growth.

What Investors Should Watch

Investors may focus on organic-sales trends across the self-care, specialty-care and infant-formula segments, whether the second half strengthens as guided, margin trends as manufacturing under-absorption moderates, and progress toward returning to organic growth. Evidence that Perrigo can stabilize and reaccelerate its core segments while sustaining infant-formula strength would do the most to justify the fresh look.

Perrigo occupies a defensive niche in consumer health as a leading provider of store-brand and over-the-counter self-care products, a positioning that tends to benefit when consumers seek value and lower-cost alternatives, giving the company a degree of resilience across economic conditions. The quarter reflected a company still working through a period of softer sales, with declines in its core self-care and specialty segments partly offset by notable strength in infant formula, and results beat expectations while management reaffirmed guidance and pointed to a sequentially stronger second half.